Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
425 participants
INTERVENTIONAL
2008-01-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy
NCT05080959
A National Center for Persistent Severe Pain After Groin Hernia Repair
NCT03713047
Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair
NCT00146198
Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair
NCT02065219
Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair
NCT02065804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3
Pregabalin
150 mg BID
4
placebo
Placebo
2
Pregabalin
75 mg BID
1
Pregabalin
25 mg BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
150 mg BID
placebo
Placebo
Pregabalin
75 mg BID
Pregabalin
25 mg BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.
* The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.
* The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.
Exclusion Criteria
* Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.
* Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.
17 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Glendale, California, United States
Pfizer Investigational Site
Laguna Hills, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Lake Worth, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Rochester, Minnesota, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Stony Brook, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Hermitage, Tennessee, United States
Pfizer Investigational Site
Hermitage, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Humble, Texas, United States
Pfizer Investigational Site
Kingwood, Texas, United States
Pfizer Investigational Site
Randwick, New South Wales, Australia
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Charlottetown, Prince Edward Island, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Vadodara, Gujarat, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Madurai, Tamil Nadu, India
Pfizer Investigational Site
Delhi, , India
Pfizer Investigational Site
Alcorcón, Madrid, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Gävle, , Sweden
Pfizer Investigational Site
Landskrona, , Sweden
Pfizer Investigational Site
Mora, , Sweden
Pfizer Investigational Site
Örebro, , Sweden
Pfizer Investigational Site
Skellefteå, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081171
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.